baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

JP Morgan Put 40 BMY 17.01.2025/ DE000JB68BF8 /

20/05/2024 08:34:12	Chg.0.000	Bid14:08:11	Ask14:08:11	Underlying	Strike price	Expiration date	Option type
0.180EUR	0.00%	- Bid Size: -	- Ask Size: -	Bristol Myers Squibb...	40.00 USD	17/01/2025	Put

GlobeNewswire 16/05 CytomX Therapeutics Announces New Employment Inducement Grants

GlobeNewswire 15/05 Lantheus Announces Executive Appointments to Accelerate Innovation

GlobeNewswire 14/05 Firefly Neuroscience, an AI-Driven Brain Health Company, Appoints Healthcare-Industry Executive, Dav...

GlobeNewswire 14/05 Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...

GlobeNewswire 13/05 Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update

GlobeNewswire 08/05 CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 08/05 Immunocore reports first quarter financial results and provides a business update

GlobeNewswire 07/05 CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...

GlobeNewswire 02/05 Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., ...

GlobeNewswire 01/05 Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration

GlobeNewswire 01/05 CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clin...

GlobeNewswire 30/04 Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

GlobeNewswire 30/04 CHARM Therapeutics appoints Dr Nicholas Edmunds as Chief Development Officer, Head of Pre-Clinical D...

GlobeNewswire 25/04 International Myeloma Foundation Holds 15th Annual Gala at the Edison Ballroom in New York City on A...

GlobeNewswire 25/04 Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract ...

GlobeNewswire 25/04 Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes ...

GlobeNewswire 22/04 ArriVent Appoints Kristine Peterson to its Board of Directors

GlobeNewswire 08/04 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Sq...

GlobeNewswire 08/04 Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer

GlobeNewswire 08/04 TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H.,...

GlobeNewswire 08/04 CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Dire...

GlobeNewswire 05/04 Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies D...

GlobeNewswire 03/04 Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the...

GlobeNewswire 03/04 CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engag...

GlobeNewswire 02/04 MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered ...

JP Morgan Put 40 BMY 17.01.2025/ DE000JB68BF8 /

If you wish to receive reply to your feedback, please provide your email address.